SkyePharma Reacquires European Rights for DepoBupivacaine(TM).
Publication: PR Newswire
Publication Date: 30-JUN-06
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
LONDON, June 30 /PRNewswire-FirstCall/ -- SkyePharma PLC ( LSE: SKP) announces that it has completed negotiations with Mundipharma International Holdings Limited ("Mundipharma") the result of which is that SkyePharma will reacquire the rights for the marketing and distribution of DepoBupivacaine(TM) in Europe and other international markets excluding the USA, Canada and Japan. SkyePharma will also obtain rights to the clinical data from the Phase II trials of DepoBupivacaine(TM). This is expected to simplify the ongoing divestment process of SkyePharma's injectables unit.
SkyePharma's Chief Executive Frank Condella said: "DepoBupivacaine(TM) is the most important near-term product in the injectables pipeline and therefore a key component of the value of this business unit. During our negotiations to divest this unit we have identified the desirability of clarifying the commercial rights to this key product and we are gratified that we are now in a position...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
